Heterocyclic amino substituted heteroaryl fused pyridines; GABA brain receptor ligands
US6423711B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Dec 13, 2000 |
| Grant date | Jul 23, 2002 |
| Priority date | — |
| Expiry date | Dec 13, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D495/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Disclosed are compounds of the formula or the pharmaceutically acceptable non-toxic salts thereof wherein:n is an integer from 0 to 3;the C ring is aryl or heteroaryl;X is CH, N, or OZ represents an electron pair, hydrogen, or (un)substituted heterocycle, aryl, or amido;W is (un)substituted alkyl, aryl, or heteroaryl;A and B are hydrogen or lower alkyl,which compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors. These compounds are useful in the diagnosis and treatment of anxiety, Down Syndrome, sleep, cognitive and seizure disorders, and overdose with benzodiazepine drugs and for enhancement of alertness.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.